Literature DB >> 8622890

Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas.

R Ferracini1, M Olivero, M F Di Renzo, M Martano, C De Giovanni, P Nanni, G Basso, K Scotlandi, P L Lollini, P M Comoglio.   

Abstract

The MET oncogene encodes the receptor for HGF/Scatter Factor, known to control cell motility and invasion in epithelial cells. We report that the Met/HGF receptor, absent in differentiated adult skeletal muscles, is aberrantly expressed in clinical samples and in established cell lines of human rhadbomyosarcomas. In both the embryonal and alveolar histotypes the oncogene is overexpressed and, in some cases, amplified. The Met receptor is exposed at the cell surface and is functionally active in response to HGF/Scatter Factor. Accordingly, rhabdomyosarcoma cells exhibit an invasive phenotype in vitro in response to exogenous HGF/Scatter factor. As the factor is known to be produced by connective tissues, a paracrine stimulation of rhabdomyosarcoma invasiveness in vivo is hypothesized. Two alveolar rhabdomyosarcomas were found in co-express the ¿two-kringle' alternatively-spliced HGF/Scatter Factor variant, which has been previously shown to stimulate cell motility and matrix invasion in vitro. These cells displayed the invasive phenotype in the absence of exogenous HGF/Scatter Factor, suggesting an autocrine mechanism in vivo. These data indicate that aberrant expression of the MET proto-oncogene provides rhabdomyosarcoma cells with the same property as embryonal myoblasts to migrate into the surrounding connective tissues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622890

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

Review 1.  Invasive growth: from development to metastasis.

Authors:  Paolo M Comoglio; Livio Trusolino
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

2.  Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma.

Authors:  A Pandita; M Zielenska; P Thorner; J Bayani; R Godbout; M Greenberg; J A Squire
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

3.  Induction of c-met proto-oncogene expression at the metastatic site.

Authors:  J Imai; M Watanabe; M Sasaki; R Yamaguchi; S Tateyama; S Sugano
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

4.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

5.  Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Authors:  Simona Cignetto; Chiara Modica; Cristina Chiriaco; Lara Fontani; Paola Milla; Paolo Michieli; Paolo M Comoglio; Elisa Vigna
Journal:  Mol Oncol       Date:  2016-03-28       Impact factor: 6.603

6.  Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor.

Authors:  H Takayama; W J LaRochelle; R Sharp; T Otsuka; P Kriebel; M Anver; S A Aaronson; G Merlino
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

7.  Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.

Authors:  Peter J Houghton; Raushan T Kurmasheva; E Anders Kolb; Jianrong Wu; Richard Gorlick; John M Maris; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-09-09       Impact factor: 3.167

8.  Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.

Authors:  Kyung Hee Lee; Eun Young Choi; Myung Soo Hyun; Byung Ik Jang; Tae Nyeun Kim; Heon Ju Lee; Jong Yuel Eun; Hong Gin Kim; Sung Soo Yoon; Dong Sik Lee; Jung Hye Kim; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2007-11-09       Impact factor: 5.150

9.  Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling.

Authors:  Yi Guo; Jun Xie; Elyssa Rubin; Ya-Xiong Tang; Fritz Lin; Xiaolin Zi; Bang H Hoang
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 10.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.